Gossamer Bio Inc (GOSS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gossamer Bio Inc (GOSS) has a cash flow conversion efficiency ratio of 0.439x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.17 Million) by net assets ($-82.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gossamer Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GOSS current and long-term liabilities for a breakdown of total debt and financial obligations.
Gossamer Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gossamer Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marisa Lojas S.A
SA:AMAR3
|
0.317x |
|
Alcadon Group AB
ST:ALCA
|
0.063x |
|
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
|
-0.014x |
|
Overseas Commerce Ltd
TA:OVRS
|
0.088x |
|
SinoMedia Holding Limited
F:SJY
|
0.010x |
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
-0.051x |
|
United Bancorp Inc
NASDAQ:UBCP
|
0.045x |
|
MLG OZ Ltd
AU:MLG
|
0.297x |
Annual Cash Flow Conversion Efficiency for Gossamer Bio Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Gossamer Bio Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Gossamer Bio Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $29.49 Million | $-3.47 Million | -0.118x | +95.36% |
| 2023-12-31 | $62.77 Million | $-159.16 Million | -2.536x | +83.63% |
| 2022-12-31 | $12.08 Million | $-187.03 Million | -15.487x | -895.85% |
| 2021-12-31 | $121.46 Million | $-188.89 Million | -1.555x | -182.78% |
| 2020-12-31 | $320.68 Million | $-176.36 Million | -0.550x | -33.84% |
| 2019-12-31 | $352.49 Million | $-144.83 Million | -0.411x | -196.65% |
| 2018-12-31 | $-120.07 Million | $-51.04 Million | 0.425x | -49.22% |
| 2017-12-31 | $-6.86 Million | $-5.75 Million | 0.837x | +614.89% |
| 2016-12-31 | $-123.00K | $20.00K | -0.163x | -- |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more